<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599534</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 07.0135</org_study_id>
    <nct_id>NCT00599534</nct_id>
  </id_info>
  <brief_title>Controlled Trial on Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome</brief_title>
  <official_title>A Randomized Double Blind Controlled Trial on the Effect of Treatment in Children With Obstructive Sleep Apnea Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral therapy with montelukast may lead to improved polysomnographic findings in children with&#xD;
      mild to moderate OSAS with and without allergic rhinitis who a priori require T&amp;A for OSAS.&#xD;
&#xD;
      - A significant proportion of the children with OSAS treated with montelukast will show&#xD;
      reduced severity of OSAS, and this will obviate the need for surgical T&amp;A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Specific Aim. To conduct a randomized double blind 16-week trial comparing the effect&#xD;
      on polysomnographic measures of the administration of once a day oral montelukast therapy vs.&#xD;
      placebo in children with OSAS.&#xD;
&#xD;
      Secondary Specific Aim. For all children with the original AHI at diagnosis of &gt;2 hrTST, we&#xD;
      expect improvements in the severity of sleep apnea to occur following treatment with&#xD;
      montelukast. Therefore, we will examine the overall reduction in AHI and also how many of&#xD;
      these children have AHI&lt; 2 after the 16-week treatment. In other words, the percentage of&#xD;
      children converting from needing T&amp;A surgery before treatment with montelukast to not needing&#xD;
      surgery after treatment will be examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigator has transferred to another Institution&#xD;
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of children converting from needing T&amp;A surgery before treatment with montelukast to not needing surgery after treatment will be examined.</measure>
    <time_frame>Duration of Study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg tablet for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 mg for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>4 mg oral tablets</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5mg tablets</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic snoring children &gt; 2 years of age and &lt; 10 years of age, who snore and&#xD;
             have an apnea hypopnea index (AHI) &gt;2/hrTST (hour total sleep time), and in whom T&amp;A&#xD;
             is therefore contemplated. Also among these, we will include children referred for&#xD;
             evaluation for snoring who have a history of allergic rhinitis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to montelukast&#xD;
&#xD;
          -  Immunodeficiency or immunosuppressant therapy&#xD;
&#xD;
          -  Craniofacial, neuromuscular, syndromic or defined genetic abnormalities&#xD;
&#xD;
          -  Acute upper respiratory tract infection&#xD;
&#xD;
          -  Systemic corticosteroid therapy or antibiotic therapy in the 2 weeks previous to the&#xD;
             study&#xD;
&#xD;
          -  Children who already had adenotonsillectomy.&#xD;
&#xD;
        In addition, children chronically receiving oral antihistamine preparations or nasal&#xD;
        decongestants will be required to continue using these medications throughout the duration&#xD;
        of the study. Patients receiving immunotherapy will continue on the same regimen without&#xD;
        escalation of dose and frequency throughout the duration of the study. In addition,&#xD;
        patients with severe OSA who in the opinion of their treating physicians require early&#xD;
        surgical intervention for their OSA will be excluded from eligibility to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leila Kheirandish, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lelia Kheirandish</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville Pediatric Sleep Medicine Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Pediatrics Sleep Medicine Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

